Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Michael Ryskin, an analyst from Bank of America Securities, maintained the Sell rating on Illumina (ILMN – Research Report). The associated price target remains the same with $105.00. Michael Ryskin’s ...

Canaccord Genuity analyst Kyle Mikson CFA has maintained their neutral stance on ILMN stock, giving a Hold rating today. Geoff Meacham has given his Hold rating due to a combination of factors ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Illumina operates in the genetic and genomic analysis sector, providing products and services for research and clinical environments. The company's strategic priorities include achieving top-line ...

The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing ...

Wall Street analysts forecast that Illumina (ILMN) will report quarterly earnings of $0.87 per share in its upcoming release, pointing to a year-over-year increase of 163.6%. It is anticipated that ...

Analysts on Wall Street project that Illumina (ILMN) will announce quarterly loss of $0.05 per share in its forthcoming report, representing a decline of 135.7% year over year. Revenues are projected ...